The Nifty Pharma index has gained 10.07% on a year-to-date basis as of May 18, 2026, sharply outperforming the benchmark Nifty50, which has declined 9.5% over the same period. According to reports from Business Standard, this outperformance is unfolding against a challenging domestic economic landscape where compounding energy shocks could fundamentally alter India's near-term macro trajectory. VK Vijayakumar, chief investment strategist at Geojit Investments, noted that high crude prices could impact India's economic growth this year, potentially bringing it down to 6% if crude prices remain around $100 for another couple of months.
The pharma sector is positioned as a safe bet due to its inelastic demand characteristics that remain steady even during inflation or economic slowdowns. As reported by Business Standard, Vijayakumar explained that pharma demand does not depend on product pricing but rather on whether patients need medications for specific diseases. Additionally, a steadily depreciating rupee, which has recently hit record lows of ₹96.96 against the US dollar, has turned into a major structural tailwind for export-oriented drugmakers. Market expert Avinash Gorakshakar noted that with 70 to 90% of top-tier pharmaceutical revenues originating from overseas markets like the US and Europe, every dollar earned yields higher rupee-denominated earnings for these companies.
Leading the index gains are Aurobindo Pharma, which surged 26.8% Y-T-D, and Gland Pharma, up 25.2% Y-T-D. According to Business Standard, other major players have also posted resilient returns, including Laurus Labs rising 19.8%, Sun Pharma advancing 10.5%, and Cipla holding steady with a 4.6% Y-T-D return. Market expert Gorakshakar highlighted that most pharma companies reported strong double-digit growth in Q4FY26 results, with earnings growth being the real trigger that markets are responding to.
The pharma sector is positioned as insulated from digital disruption compared to other sectors, with Gorakshakar noting that AI tools can only be used as facilitators by smaller players while the core of the pharma sector remains heavily dependent on years of intensive product R&D and validation. As reported by Business Standard, from a long-term investment perspective, Gorakshakar prefers scale and institutional strength, recommending large-cap companies like Sun Pharma, Lupin, Torrent Pharma, and Mankind Pharma as preferred bets in the pharmaceutical space. Vijayakumar suggested investors should focus on companies with good track records and strong presence in the API and CDMO space.
